@FiercePharma: India's Kumar eyes a one-stop shop on pharmaceuticals. FiercePharmaAsia story | Follow @FiercePharma
@EricPFierce: See which companies had the most Class I recalls in recent years. Feature from FiercePharmaManufacturing | Follow @EricPFierce
> A transatlantic trade deal will force the FDA and European Medicines Agency to standardize their regulations on manufacturing and trials, an Eli Lilly ($LLY) executive recently said. Report
> Lundbeck said a new data analysis showed its long-lasting antipsychotic injection Abilify Maintena beat head-to-head rival Invega Sustenna at improving functioning and quality of life in young people with schizophrenia. Release
> Mylan ($MYL) CFO John Sheehan said the company wants to join the Tel Aviv Stock Exchange (TASE) if it succeeds in buying Perrigo ($PRGO); it would be among the largest publicly traded companies on Israel's exchange. Report
> Pozen, which just swapped CEOs and engineered a tax-inversion buyout, brought in three new top managers to lead the combined company, which will be called Aralez Pharmaceuticals. Report
> Morris Plains, NJ, cracked down on environmental remediation plans for a former Pfizer ($PFE) site in the borough. Report
> NeuroRx said a small study of a ketamine drug combination reduced symptoms of depression and suicidal tendencies in patients with bipolar disorder. Report
Medical Device News
@FierceMedDev: Broad Institute bags $20M for drug-resistant TB research. More from FierceDiagnostics | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: Medtronic strikes back with FDA approval of its third-gen TAVR. Report | Follow @VarunSaxena2
@EmilyWFierce: Cue the screaming fans: Nick Jonas signs up with Dexcom diabetes effort. FiercePharmaMarketing story | Follow @EmilyWFierce
> The Esophageal Cooling Device gets FDA's rare de novo clearance for innovative devices. Article
> Philips readies launch of smart device-based ultrasound device, app. Story
Biotech News
@FierceBiotech: Chris Viehbacher explains: "If I had $2 billion to invest ..." More | Follow @FierceBiotech
@JohnCFierce: Cool new video on Cellectis's allogeneic approach to T cells. It looks so easy... Watch | Follow @JohnCFierce
@DamianFierce: Analyst on $ADHD call: "congrats on these interesting observations." Their drug was outperformed by placebo, dude. | Follow @DamianFierce
> Langer startup SQZ hopes to spark a tech revolution in immuno-oncology. Article
> Hackers are targeting biotech with eyes on insider trading. Report
Biotech Research News
> Team spotlights new evidence that Parkinson's starts in the gut. Story
> Allied-Bristol JV picks up rights to Harvard's work on traditional Chinese remedy. News
> Experimental prostate cancer combo shows promise in case studies. Report
> Purdue group finds Achilles' heel for MERS. Item
> Investigators say they've designed a new-and-improved antibiotic. Article
Diagnostics News
> Qiagen to partner with Japan's Hitachi on molecular testing. More
> Broad Institute bags $20M for drug-resistant TB research. Item
> Advanced Cell Diagnostics receives $22M to develop its RNA biomarker tech. News
> Siemens snags FDA approval for HIV combo test. Story
> Biodesix brings Series E to $38M for blood-based lung cancer Dx. Article
Pharma Marketing News
> Another AZ exec jumps ship for CEO job at smaller drugmaker. Item
> Novartis playing catch-up in cancer? Not us, says top oncology exec. Story
> Has Lundbeck failed to sharpen Brintellix's marketing edge with payers? More
> Call it Allergan, call it a 'growth pharma.' Just don't call it Big Pharma. Article
> Got game? Pharma's moving into gamification but needs to drop the bribes. Report
And Finally... An 18-year-old Thiel Fellow postponed college for a year to develop and sell GlucoIQ, his platform for doctors to use in managing diabetes patients' medications and outcomes. Report